Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pyrimethamine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Azithromycin | DRUG | - |
| Pyrimethamine | DRUG | - |
| Leucovorin calcium | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia (PCP). * Allowed during maintenance period (weeks 7 - 24): * Zidovudine and other antiretrovirals available through treatment IND mechanisms, ganciclovir, and mainte...
Pyrimethamine is a small molecule drug being studied for the treatment of cerebral toxoplasmosis, a brain infection, in patients with AIDS. It is currently in Phase 1 clinical development and is being developed by Pfizer, Inc. for the infectious disease therapeutic area.
Pyrimethamine is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for the treatment of cerebral toxoplasmosis.
Pyrimethamine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed for the treatment of cerebral toxoplasmosis.
Pyrimethamine has one completed clinical trial, NCT00000966, titled 'A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS.' This Phase 1 study enrolled 45 participants in the United States and was not randomized or double-blinded.
Pyrimethamine is a small molecule drug. It is being studied for the treatment of cerebral toxoplasmosis, a brain infection that commonly affects patients with AIDS. The drug is administered in combination with azithromycin in the clinical trial.